Study S001867

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly As Add-on Therapy to Metformin And/or Sulfonylureas in Patients with Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT06716216
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: RECRUITING
Enrollment: 537
Start: 2024-11-29
Primary completion: 2026-03-20
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:Drug: 5 mg BGM0504 Administered SC; DRUG:Drug:10 mg BGM0504 Administered SC; DRUG:Drug: Semaglutide Administered SC
Results posted: FALSE

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.